about
DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriersLarge-scale genotyping identifies 41 new loci associated with breast cancer risk.Germline BRCA1/2 mutation testing is indicated in every patient with epithelial ovarian cancer: A systematic review.Exome sequencing of germline DNA from non-BRCA1/2 familial breast cancer cases selected on the basis of aCGH tumor profiling.Timing of risk reducing mastectomy in breast cancer patients carrying a BRCA1/2 mutation: retrospective data from the Dutch HEBON studyGenomewide high-density SNP linkage analysis of non-BRCA1/2 breast cancer families identifies various candidate regions and has greater power than microsatellite studies.Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics.A family history of breast cancer will not predict female early onset breast cancer in a population-based settingDesign of the BRISC study: a multicentre controlled clinical trial to optimize the communication of breast cancer risks in genetic counsellingA simple method for co-segregation analysis to evaluate the pathogenicity of unclassified variants; BRCA1 and BRCA2 as an example.Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation CarriersValidation of a scale for assessing attitudes towards outcomes of genetic cancer testing among primary care providers and breast specialists.Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT studyOpening the psychological black box in genetic counseling. The psychological impact of DNA testing is predicted by the counselees' perception, the medical impact by the pathogenic or uninformative BRCA1/2-result.Common variants of the BRCA1 wild-type allele modify the risk of breast cancer in BRCA1 mutation carriers.Exposure to diagnostic radiation and risk of breast cancer among carriers of BRCA1/2 mutations: retrospective cohort study (GENE-RAD-RISK).Breast cancer risk and 6q22.33: combined results from Breast Cancer Association Consortium and Consortium of Investigators on Modifiers of BRCA1/2Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction.MicroRNA related polymorphisms and breast cancer risk.A whisper-game perspective on the family communication of DNA-test results: a retrospective study on the communication process of BRCA1/2-test results between proband and relatives.Whole exome sequencing suggests much of non-BRCA1/BRCA2 familial breast cancer is due to moderate and low penetrance susceptibility alleles.Evidence for SMAD3 as a modifier of breast cancer risk in BRCA2 mutation carriers.The effectiveness of a graphical presentation in addition to a frequency format in the context of familial breast cancer risk communication: a multicenter controlled trial.Evaluation of the XRCC1 gene as a phenotypic modifier in BRCA1/2 mutation carriers. Results from the consortium of investigators of modifiers of BRCA1/BRCA2.Genetic testing for familial/hereditary breast cancer-comparison of guidelines and recommendations from the UK, France, the Netherlands and Germany.General Practitioners and Breast Surgeons in France, Germany, Netherlands and the UK show variable breast cancer risk communication profilesHaplotype structure in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriersTumour characteristics and prognosis of breast cancer patients carrying the germline CHEK2*1100delC variantAllele-specific regulation of FGFR2 expression is cell type-dependent and may increase breast cancer risk through a paracrine stimulus involving FGF10FANCM c.5791C>T nonsense mutation (rs144567652) induces exon skipping, affects DNA repair activity and is a familial breast cancer risk factorAssociation of PHB 1630 C>T and MTHFR 677 C>T polymorphisms with breast and ovarian cancer risk in BRCA1/2 mutation carriers: results from a multicenter study.MUTYH gene variants and breast cancer in a Dutch case–control study.A nonsynonymous polymorphism in IRS1 modifies risk of developing breast and ovarian cancers in BRCA1 and ovarian cancer in BRCA2 mutation carriers.Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers.Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores.Clinical correlates of low-risk variants in FGFR2, TNRC9, MAP3K1, LSP1 and 8q24 in a Dutch cohort of incident breast cancer cases.Prediction of breast cancer risk based on profiling with common genetic variantsRisk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriersGenetic counselling and the intention to undergo prophylactic mastectomy: effects of a breast cancer risk assessmentCommon alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers.
P50
Q21144874-C9840B78-930E-4C89-B2DE-5F4F96F1BB1DQ29416989-8349B366-4502-4DB4-AB50-B34591022634Q30250240-8F5AD4EC-EC93-495D-987B-C9CF2C794A44Q30458477-9E13BBB7-9B6E-430E-9947-4156E91F3AC5Q30896495-F038D1BB-6545-45AD-BD45-E3C6E7E77EAAQ33296082-A28B6426-9E79-4D91-85DB-81C19926A26EQ33330850-F32ED12D-13C3-4BB7-9C1D-39AE8A72ABB7Q33354606-3D45D0D6-2F22-4AAE-B6E3-DBCF7FB195BCQ33373818-3860F723-DBA9-405E-A7A4-2288759BCDEEQ33475933-64C6C1E6-D85D-4702-9AD0-904E951EFE08Q33614244-D0FB4218-BBA3-485C-B908-CABE1715FDEDQ33751777-94C72D5B-0E14-419B-8652-BED9A5C89148Q33927384-D2659768-BCBC-4A72-BBBF-E866A26C667EQ34149456-BB385FB2-589D-4A87-A8A3-F9E8AACA0C6FQ34213403-D79B0434-CEE2-49C1-95E5-C26238DD3055Q34298114-D03EB0FB-10E0-4674-8297-60D5C207B102Q34327945-9FCCAE4A-6AF3-4F32-B58B-40F3D6A45E0EQ34394665-8CC157E9-9B96-416B-8B69-8701535EE9F0Q34497352-421FB473-6F6C-4C8B-B50E-D7F0939E0AFFQ34565161-E5A4D03C-8BAE-474A-882A-61C41ACBA4D7Q34586198-EF5ACD95-52D4-417F-A629-AAFFBB0FA7BFQ34613604-CE466EE6-960B-4882-99B9-DA90861083E8Q34693902-CEE84EC5-2A45-48EA-A781-C9D68A77732BQ34806825-AB451DF3-D3C5-469A-A79F-697A5C2219DBQ35263848-FB690C82-F80E-4F64-9BA8-A3A7147D343EQ35372433-ACD44D32-CEA0-4F32-A9B4-66A18D5EF708Q35382206-D385BDD9-15E4-41BC-B5E3-4A4B670D7525Q35443960-63676F9F-0943-4279-B86D-D05DEB1EE8BBQ35608687-B7503190-A341-4105-9B93-7505EFDC55C7Q35999309-06945F12-C458-42A2-9802-292597DF04D3Q36072765-931A7FBD-C195-4109-9EAF-F77CB3DED107Q36095933-78C21F79-E584-487D-88D4-F9AC1446909EQ36152991-BA9655D8-F4F6-4417-98DB-7DF92D1C3EA2Q36280191-DC800BCF-F5FA-4FA1-9967-8DA7199453C5Q36356727-4AE82803-ECBC-4674-9046-706FCA15F464Q36465283-75D901D8-563D-4E29-A5A2-B22190D98677Q36583004-0F3A675D-62C2-49B9-8B2C-C23BD5554C30Q36615112-11CE38F2-DE16-4C57-9E9B-EB31EFFD3EB9Q36648955-F79B9B2B-501A-4CE9-844C-3BC8A0A212ECQ36839777-CDF7CA38-30EC-4758-804D-59EAECB729D9
P50
description
onderzoeker
@nl
researcher, ORCID id # 0000-0002-1436-7650
@en
name
Christi J van Asperen
@en
Christi van Asperen
@nl
type
label
Christi J van Asperen
@en
Christi van Asperen
@nl
altLabel
C. van Asperen
@nl
C.J. van Asperen
@nl
Christi J van Asperen
@nl
Christi van Asperen
@en
prefLabel
Christi J van Asperen
@en
Christi van Asperen
@nl
P1006
P1006
P31
P496
0000-0002-1436-7650
P7449
PRS1252746